Medtech Industry Posts $325 Billion in Revenue for H1
The sector is scaling through aggressive M&A and the rapid integration of artificial intelligence into clinical devices.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you trust that the increasing use of AI in medical devices will improve patient outcomes?
The global medical technology industry generated $325 billion in revenue during the first half of 2026, marking a 7.1% increase compared to the first half of 2025. Operators in the sector are navigating this growth through increased M&A activity and the rapid integration of artificial intelligence into clinical care pathways.
Why it matters
The sector's steady revenue expansion and heavy investment in AI-enabled device development signal a shift toward high-tech diagnostic and treatment workflows. Businesses are scaling through significant consolidation as they look to capture market share in an increasingly automated healthcare environment.
The medtech industry reached $325 billion in revenue for the first half of 2026, a 7.1% increase over the same period in 2025. This follows a 2025 fiscal year that saw $650 billion in total revenue and $130 billion in disclosed M&A activity, highlighted by Abbott's $23 billion acquisition of Exact Sciences.
The players
Abbott
A diversified global healthcare company specializing in diagnostics, medical devices, and branded generic medicines.
Exact Sciences
A molecular diagnostics company focused on early cancer detection and screening tests.
The details
Companies are driving this growth by embedding AI into medical devices to optimize diagnostic speed and patient outcomes. Regulatory pipelines reflect this shift, with the FDA authorizing 331 AI-enabled devices in 2025 alone, contributing to a total of nearly 800 approvals between 2022 and 2025. Meanwhile, the sector is aggressively consolidating, using large-scale acquisitions to integrate specialized diagnostic capabilities into broader portfolios.
Timeline
2020-2022: FDA authorized 400 AI-enabled devices.
2022-2025: FDA authorized nearly 800 AI-enabled devices.
2025: Industry revenue reached $650 billion.
2025: FDA authorized 331 AI-enabled devices.
H1 2026: Industry revenue reached $325 billion.
Market Landscape
The rapid acceleration of FDA AI-enabled device authorizations since 2020 underscores the industry's shift toward embedded diagnostic automation. This current revenue growth tracks with the surge in regulatory clearances for AI-enabled tools, marking a transition from experimental technology to standard clinical deployment.
Operators should evaluate how their current service models incorporate AI-driven diagnostics to remain competitive in an increasingly consolidated market. Keep a close watch on the pace of AI device authorizations as these technologies continue to influence clinical expectations and procurement cycles.
The takeaway
The sector's growth is increasingly tethered to the successful scaling of artificial intelligence within the clinical supply chain. Monitor M&A activity among smaller diagnostic firms as these companies increasingly become targets for large-cap players looking to fortify their AI-enabled portfolios.
Further reading
For broader trends in medical innovation and regulatory updates, visit the Healthcare section.
Live Poll
Do you trust that the increasing use of AI in medical devices will improve patient outcomes?
